SOD1 and amyotrophic lateral sclerosis: However, several candidate compounds for ALS therapy [123] address aspects of SOD1 mutants, such as oxidative stress, impaired metal binding, and defects in protein folding, that we have also identified as affected in the motor cortex of sporadic, non-SOD1-linked patients.